Literature DB >> 2178286

Thrombocytosis in malignant pleural mesothelioma.

V De Pangher Manzini1, A Brollo, C Bianchi.   

Abstract

The prevalence of thrombocytosis (defined as a platelet count above 400,000/mm3 in at least two examinations) and the prevalence of thromboembolism were retrospectively investigated in a series of 41 patients with malignant pleural mesothelioma and in 40 subjects with non small cell lung carcinoma. All the patients were examined at necropsy. The mesothelioma patients showed a higher prevalence of thrombocytosis (56.8% vs 24.2%; p less than 0.01). However, the prevalences of thromboembolism were similar in the two groups of patients (36.6% and 32.5% respectively). Among those with mesothelioma the prevalence of thrombocytosis varied widely from one histological type to another (76.9% in mixed type, 57.1% in the epithelial, and 30% in the sarcomatous type), the difference between mixed and sarcomatous being statistically significant (p less than 0.01). Moreover, the mesothelioma patients of under 70 years had thrombocytosis more often than those over 70 (80% vs 29.4%; p less than 0.01).

Entities:  

Mesh:

Year:  1990        PMID: 2178286     DOI: 10.1177/030089169007600613

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

Authors:  T Nakano; A P Chahinian; M Shinjo; A Tonomura; M Miyake; N Togawa; K Ninomiya; K Higashino
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

2.  Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites.

Authors:  Zachary Field; Andreas Zori; Vikas Khullar; Manoela Mota; Michael Feely; Roberto J Firpi
Journal:  ACG Case Rep J       Date:  2018-03-14

3.  Malignant peritoneal mesothelioma in a patient with intestinal fistula, incisional hernia and abdominal infection: A case report.

Authors:  Sen Hong; Miao-Miao Bi; Ping-Wei Zhao; X U Wang; Qing-Yang Kong; Yong-Tao Wang; Lei Wang
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.